摘要
目的:探讨重组人促红细胞生成素治疗血液透析患者肾性贫血的临床疗效。方法:收治血液透析肾性贫血患者76例,给予重组人促红细胞生成素治疗,观察临床疗效。结果:患者治疗3个月后血红蛋白、白蛋白的水平显著高于治疗前(P<0.05)。患者治疗6个月后血红蛋白、白蛋白的水平显著高于治疗3个月(P<0.05)。结论:重组人促红细胞生成素治疗血液透析患者肾性贫血的临床疗效较好。
Objective:To investigate the clinical effect of recombinant human erythropoietin in the treatment of renal anemia in patients with hemodialysis.Methods:76 cases of patients with hemodialysis and renal anemia were treated with recombinant human erythropoietin,and the clinical effect was compared.Results:The levels of hemoglobin and albumin in patients after three months of treatment were significantly higher than those before treatment (P<0.05).The levels of hemoglobin and albumin in patients after six months of treatment were significantly higher than those after three months of treatment (P<0.05).Conclusion:Recombinant human erythropoietin in the treatment of renal anemia in patients with hemodialysis had better clinical effect.
作者
郭建秧
Guo Jianyang(The First People's Hospital of Xundian County(Yunnan Province)655200)
出处
《中国社区医师》
2017年第7期49-50,共2页
Chinese Community Doctors
